Global Human Immunoglobulin research

Human Immunoglobulin Comprehensive Study by Type (Intramuscular Injection, Intravenous Injection), Application (Disease Prevention, Treatment, Diagnosis, Other), End Users (Hospitals, Clinics, Home care), Form (Liquid, Lyophilized), Indication (Primary immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Immune Thrombocytopenic Purpura, Multifocal Motor Neropathy) Players and Region - Global Market Outlook to 2030

Human Immunoglobulin Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Human Immunoglobulin
Human immunoglobulin consists of antibodies and is made from the blood plasma. It binds itself to the particular antigens such as viruses which helps in their destruction. The preparations of immunoglobulin are concentrated, purified and filtered so that there is zero transmission of infectious disease. It is used for the treatment of immunodeficiency, ITP and leukemia. In addition, it also helps to reduce the infection in the patient at high risk. These advantages of human immunoglobulin are increasing the demand.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR6.8%


This market is fragmented by market leading players those are high focusing on production technologies, improving production efficiency and service life. With the growing number of opportunities in the market, these market potentials are captured by tracking the ongoing process improvement and by invest in market strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Human Immunoglobulin market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Shire (United States), CSL (United States), Grifols (Spain), Octapharma (Switzerland), Biotest (Germany), China National Pharmaceutical Group Corporation (China), Hualan Bio (China), Shanxi Kangbao Biological Product (China), Pfizer Inc. (United States) and Kedrion Biopharma Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Shuanglin Bio Pharma (China) and Sichuan Yuanda Shuyang Pharmaceutical (China).

Segmentation Overview
AMA Research has segmented the market of Global Human Immunoglobulin market by Type (Intramuscular Injection and Intravenous Injection), Application (Disease Prevention, Treatment, Diagnosis and Other) and Region.



On the basis of geography, the market of Human Immunoglobulin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Hospitals will boost the Human Immunoglobulin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Form , the sub-segment i.e. Liquid will boost the Human Immunoglobulin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Primary immunodeficiency will boost the Human Immunoglobulin market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Adoption of Subcutaneous owing to Improved Patients Advantages

Market Growth Drivers:
Rising Number of Hemophilic Patients is Fueling the Market Growth and Increasing Prevalence of Diseases Such as Hypogammaglobulinemia

Challenges:
Lack of Awareness in Developing Economies

Restraints:
High Costs Associated with Therapy and Strict Government Regulations may hamper the Market Growth

Opportunities:
Increasing Investments in Research and Developments and Enhancements in Immunoglobulin Production Technology

Market Leaders and their expansionary development strategies

In Noveber 2024, Grifols a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for its new immunoglobulin (Ig) purification and filling facility at its Clayton, North Carolina, manufacturing campus, one of the world’s largest sites for producing plasma-derived medicines.


Key Target Audience
End-user industry players, Raw material and manufacturing equipment supplier, Instrumentation valve players, Government bodies, venture capitalists and private equity firms and Technology standards organizations, forums, alliances and association

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Intramuscular Injection
  • Intravenous Injection
By Application
  • Disease Prevention
  • Treatment
  • Diagnosis
  • Other
By End Users
  • Hospitals
  • Clinics
  • Home care

By Form
  • Liquid
  • Lyophilized

By Indication
  • Primary immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Guillain-Barre Syndrome
  • Immune Thrombocytopenic Purpura
  • Multifocal Motor Neropathy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Hemophilic Patients is Fueling the Market Growth
      • 3.2.2. Increasing Prevalence of Diseases Such as Hypogammaglobulinemia
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in Developing Economies
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Subcutaneous owing to Improved Patients Advantages
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Immunoglobulin, by Type, Application, End Users, Form , Indication and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Human Immunoglobulin (Value)
      • 5.2.1. Global Human Immunoglobulin by: Type (Value)
        • 5.2.1.1. Intramuscular Injection
        • 5.2.1.2. Intravenous Injection
      • 5.2.2. Global Human Immunoglobulin by: Application (Value)
        • 5.2.2.1. Disease Prevention
        • 5.2.2.2. Treatment
        • 5.2.2.3. Diagnosis
        • 5.2.2.4. Other
      • 5.2.3. Global Human Immunoglobulin by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Home care
      • 5.2.4. Global Human Immunoglobulin by: Indication (Value)
        • 5.2.4.1. Primary immunodeficiency
        • 5.2.4.2. Chronic Inflammatory Demyelinating Polyneuropathy
        • 5.2.4.3. Guillain-Barre Syndrome
        • 5.2.4.4. Immune Thrombocytopenic Purpura
        • 5.2.4.5. Multifocal Motor Neropathy
      • 5.2.5. Global Human Immunoglobulin Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Human Immunoglobulin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Shire (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Grifols (Spain)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Octapharma (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biotest (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. China National Pharmaceutical Group Corporation (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hualan Bio (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Shanxi Kangbao Biological Product (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kedrion Biopharma Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human Immunoglobulin Sale, by Type, Application, End Users, Form , Indication and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Human Immunoglobulin (Value)
      • 7.2.1. Global Human Immunoglobulin by: Type (Value)
        • 7.2.1.1. Intramuscular Injection
        • 7.2.1.2. Intravenous Injection
      • 7.2.2. Global Human Immunoglobulin by: Application (Value)
        • 7.2.2.1. Disease Prevention
        • 7.2.2.2. Treatment
        • 7.2.2.3. Diagnosis
        • 7.2.2.4. Other
      • 7.2.3. Global Human Immunoglobulin by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Home care
      • 7.2.4. Global Human Immunoglobulin by: Indication (Value)
        • 7.2.4.1. Primary immunodeficiency
        • 7.2.4.2. Chronic Inflammatory Demyelinating Polyneuropathy
        • 7.2.4.3. Guillain-Barre Syndrome
        • 7.2.4.4. Immune Thrombocytopenic Purpura
        • 7.2.4.5. Multifocal Motor Neropathy
      • 7.2.5. Global Human Immunoglobulin Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Immunoglobulin: by Type(USD Million)
  • Table 2. Human Immunoglobulin Intramuscular Injection , by Region USD Million (2018-2023)
  • Table 3. Human Immunoglobulin Intravenous Injection , by Region USD Million (2018-2023)
  • Table 4. Human Immunoglobulin: by Application(USD Million)
  • Table 5. Human Immunoglobulin Disease Prevention , by Region USD Million (2018-2023)
  • Table 6. Human Immunoglobulin Treatment , by Region USD Million (2018-2023)
  • Table 7. Human Immunoglobulin Diagnosis , by Region USD Million (2018-2023)
  • Table 8. Human Immunoglobulin Other , by Region USD Million (2018-2023)
  • Table 9. Human Immunoglobulin: by End Users(USD Million)
  • Table 10. Human Immunoglobulin Hospitals , by Region USD Million (2018-2023)
  • Table 11. Human Immunoglobulin Clinics , by Region USD Million (2018-2023)
  • Table 12. Human Immunoglobulin Home care , by Region USD Million (2018-2023)
  • Table 13. Human Immunoglobulin: by Indication(USD Million)
  • Table 14. Human Immunoglobulin Primary immunodeficiency , by Region USD Million (2018-2023)
  • Table 15. Human Immunoglobulin Chronic Inflammatory Demyelinating Polyneuropathy , by Region USD Million (2018-2023)
  • Table 16. Human Immunoglobulin Guillain-Barre Syndrome , by Region USD Million (2018-2023)
  • Table 17. Human Immunoglobulin Immune Thrombocytopenic Purpura , by Region USD Million (2018-2023)
  • Table 18. Human Immunoglobulin Multifocal Motor Neropathy , by Region USD Million (2018-2023)
  • Table 19. South America Human Immunoglobulin, by Country USD Million (2018-2023)
  • Table 20. South America Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 21. South America Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 22. South America Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 23. South America Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 24. South America Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 25. Brazil Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 26. Brazil Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 27. Brazil Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 28. Brazil Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 29. Brazil Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 30. Argentina Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 31. Argentina Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 32. Argentina Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 33. Argentina Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 34. Argentina Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 35. Rest of South America Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 36. Rest of South America Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 37. Rest of South America Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 38. Rest of South America Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 39. Rest of South America Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 40. Asia Pacific Human Immunoglobulin, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 42. Asia Pacific Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 43. Asia Pacific Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 44. Asia Pacific Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 45. Asia Pacific Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 46. China Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 47. China Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 48. China Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 49. China Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 50. China Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 51. Japan Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 52. Japan Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 53. Japan Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 54. Japan Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 55. Japan Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 56. India Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 57. India Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 58. India Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 59. India Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 60. India Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 61. South Korea Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 62. South Korea Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 63. South Korea Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 64. South Korea Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 65. South Korea Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 66. Taiwan Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 67. Taiwan Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 68. Taiwan Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 69. Taiwan Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 70. Taiwan Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 71. Australia Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 72. Australia Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 73. Australia Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 74. Australia Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 75. Australia Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 81. Europe Human Immunoglobulin, by Country USD Million (2018-2023)
  • Table 82. Europe Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 83. Europe Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 84. Europe Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 85. Europe Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 86. Europe Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 87. Germany Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 88. Germany Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 89. Germany Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 90. Germany Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 91. Germany Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 92. France Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 93. France Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 94. France Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 95. France Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 96. France Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 97. Italy Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 98. Italy Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 99. Italy Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 100. Italy Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 101. Italy Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 102. United Kingdom Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 103. United Kingdom Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 104. United Kingdom Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 105. United Kingdom Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 106. United Kingdom Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 107. Netherlands Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 108. Netherlands Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 109. Netherlands Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 110. Netherlands Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 111. Netherlands Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 112. Rest of Europe Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 113. Rest of Europe Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 114. Rest of Europe Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 115. Rest of Europe Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 116. Rest of Europe Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 117. MEA Human Immunoglobulin, by Country USD Million (2018-2023)
  • Table 118. MEA Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 119. MEA Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 120. MEA Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 121. MEA Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 122. MEA Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 123. Middle East Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 124. Middle East Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 125. Middle East Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 126. Middle East Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 127. Middle East Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 128. Africa Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 129. Africa Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 130. Africa Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 131. Africa Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 132. Africa Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 133. North America Human Immunoglobulin, by Country USD Million (2018-2023)
  • Table 134. North America Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 135. North America Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 136. North America Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 137. North America Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 138. North America Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 139. United States Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 140. United States Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 141. United States Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 142. United States Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 143. United States Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 144. Canada Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 145. Canada Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 146. Canada Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 147. Canada Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 148. Canada Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 149. Mexico Human Immunoglobulin, by Type USD Million (2018-2023)
  • Table 150. Mexico Human Immunoglobulin, by Application USD Million (2018-2023)
  • Table 151. Mexico Human Immunoglobulin, by End Users USD Million (2018-2023)
  • Table 152. Mexico Human Immunoglobulin, by Form USD Million (2018-2023)
  • Table 153. Mexico Human Immunoglobulin, by Indication USD Million (2018-2023)
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Human Immunoglobulin: by Type(USD Million)
  • Table 165. Human Immunoglobulin Intramuscular Injection , by Region USD Million (2025-2030)
  • Table 166. Human Immunoglobulin Intravenous Injection , by Region USD Million (2025-2030)
  • Table 167. Human Immunoglobulin: by Application(USD Million)
  • Table 168. Human Immunoglobulin Disease Prevention , by Region USD Million (2025-2030)
  • Table 169. Human Immunoglobulin Treatment , by Region USD Million (2025-2030)
  • Table 170. Human Immunoglobulin Diagnosis , by Region USD Million (2025-2030)
  • Table 171. Human Immunoglobulin Other , by Region USD Million (2025-2030)
  • Table 172. Human Immunoglobulin: by End Users(USD Million)
  • Table 173. Human Immunoglobulin Hospitals , by Region USD Million (2025-2030)
  • Table 174. Human Immunoglobulin Clinics , by Region USD Million (2025-2030)
  • Table 175. Human Immunoglobulin Home care , by Region USD Million (2025-2030)
  • Table 176. Human Immunoglobulin: by Indication(USD Million)
  • Table 177. Human Immunoglobulin Primary immunodeficiency , by Region USD Million (2025-2030)
  • Table 178. Human Immunoglobulin Chronic Inflammatory Demyelinating Polyneuropathy , by Region USD Million (2025-2030)
  • Table 179. Human Immunoglobulin Guillain-Barre Syndrome , by Region USD Million (2025-2030)
  • Table 180. Human Immunoglobulin Immune Thrombocytopenic Purpura , by Region USD Million (2025-2030)
  • Table 181. Human Immunoglobulin Multifocal Motor Neropathy , by Region USD Million (2025-2030)
  • Table 182. South America Human Immunoglobulin, by Country USD Million (2025-2030)
  • Table 183. South America Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 184. South America Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 185. South America Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 186. South America Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 187. South America Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 188. Brazil Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 189. Brazil Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 190. Brazil Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 191. Brazil Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 192. Brazil Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 193. Argentina Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 194. Argentina Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 195. Argentina Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 196. Argentina Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 197. Argentina Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 198. Rest of South America Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 199. Rest of South America Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 200. Rest of South America Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 201. Rest of South America Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 202. Rest of South America Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 203. Asia Pacific Human Immunoglobulin, by Country USD Million (2025-2030)
  • Table 204. Asia Pacific Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 205. Asia Pacific Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 206. Asia Pacific Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 207. Asia Pacific Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 208. Asia Pacific Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 209. China Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 210. China Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 211. China Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 212. China Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 213. China Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 214. Japan Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 215. Japan Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 216. Japan Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 217. Japan Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 218. Japan Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 219. India Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 220. India Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 221. India Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 222. India Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 223. India Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 224. South Korea Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 225. South Korea Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 226. South Korea Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 227. South Korea Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 228. South Korea Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 229. Taiwan Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 230. Taiwan Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 231. Taiwan Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 232. Taiwan Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 233. Taiwan Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 234. Australia Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 235. Australia Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 236. Australia Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 237. Australia Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 238. Australia Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 239. Rest of Asia-Pacific Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 240. Rest of Asia-Pacific Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 241. Rest of Asia-Pacific Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 242. Rest of Asia-Pacific Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 244. Europe Human Immunoglobulin, by Country USD Million (2025-2030)
  • Table 245. Europe Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 246. Europe Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 247. Europe Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 248. Europe Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 249. Europe Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 250. Germany Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 251. Germany Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 252. Germany Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 253. Germany Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 254. Germany Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 255. France Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 256. France Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 257. France Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 258. France Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 259. France Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 260. Italy Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 261. Italy Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 262. Italy Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 263. Italy Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 264. Italy Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 265. United Kingdom Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 266. United Kingdom Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 267. United Kingdom Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 268. United Kingdom Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 269. United Kingdom Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 270. Netherlands Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 271. Netherlands Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 272. Netherlands Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 273. Netherlands Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 274. Netherlands Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 275. Rest of Europe Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 276. Rest of Europe Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 277. Rest of Europe Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 278. Rest of Europe Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 279. Rest of Europe Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 280. MEA Human Immunoglobulin, by Country USD Million (2025-2030)
  • Table 281. MEA Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 282. MEA Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 283. MEA Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 284. MEA Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 285. MEA Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 286. Middle East Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 287. Middle East Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 288. Middle East Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 289. Middle East Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 290. Middle East Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 291. Africa Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 292. Africa Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 293. Africa Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 294. Africa Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 295. Africa Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 296. North America Human Immunoglobulin, by Country USD Million (2025-2030)
  • Table 297. North America Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 298. North America Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 299. North America Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 300. North America Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 301. North America Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 302. United States Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 303. United States Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 304. United States Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 305. United States Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 306. United States Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 307. Canada Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 308. Canada Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 309. Canada Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 310. Canada Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 311. Canada Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 312. Mexico Human Immunoglobulin, by Type USD Million (2025-2030)
  • Table 313. Mexico Human Immunoglobulin, by Application USD Million (2025-2030)
  • Table 314. Mexico Human Immunoglobulin, by End Users USD Million (2025-2030)
  • Table 315. Mexico Human Immunoglobulin, by Form USD Million (2025-2030)
  • Table 316. Mexico Human Immunoglobulin, by Indication USD Million (2025-2030)
  • Table 317. Research Programs/Design for This Report
  • Table 318. Key Data Information from Secondary Sources
  • Table 319. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Immunoglobulin: by Type USD Million (2018-2023)
  • Figure 5. Global Human Immunoglobulin: by Application USD Million (2018-2023)
  • Figure 6. Global Human Immunoglobulin: by End Users USD Million (2018-2023)
  • Figure 7. Global Human Immunoglobulin: by Indication USD Million (2018-2023)
  • Figure 8. South America Human Immunoglobulin Share (%), by Country
  • Figure 9. Asia Pacific Human Immunoglobulin Share (%), by Country
  • Figure 10. Europe Human Immunoglobulin Share (%), by Country
  • Figure 11. MEA Human Immunoglobulin Share (%), by Country
  • Figure 12. North America Human Immunoglobulin Share (%), by Country
  • Figure 13. Global Human Immunoglobulin share by Players 2023 (%)
  • Figure 14. Global Human Immunoglobulin share by Players (Top 3) 2023(%)
  • Figure 15. Global Human Immunoglobulin share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 18. Shire (United States) Revenue: by Geography 2023
  • Figure 19. CSL (United States) Revenue, Net Income and Gross profit
  • Figure 20. CSL (United States) Revenue: by Geography 2023
  • Figure 21. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 22. Grifols (Spain) Revenue: by Geography 2023
  • Figure 23. Octapharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Octapharma (Switzerland) Revenue: by Geography 2023
  • Figure 25. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Biotest (Germany) Revenue: by Geography 2023
  • Figure 27. China National Pharmaceutical Group Corporation (China) Revenue, Net Income and Gross profit
  • Figure 28. China National Pharmaceutical Group Corporation (China) Revenue: by Geography 2023
  • Figure 29. Hualan Bio (China) Revenue, Net Income and Gross profit
  • Figure 30. Hualan Bio (China) Revenue: by Geography 2023
  • Figure 31. Shanxi Kangbao Biological Product (China) Revenue, Net Income and Gross profit
  • Figure 32. Shanxi Kangbao Biological Product (China) Revenue: by Geography 2023
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Kedrion Biopharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Kedrion Biopharma Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Human Immunoglobulin: by Type USD Million (2025-2030)
  • Figure 38. Global Human Immunoglobulin: by Application USD Million (2025-2030)
  • Figure 39. Global Human Immunoglobulin: by End Users USD Million (2025-2030)
  • Figure 40. Global Human Immunoglobulin: by Indication USD Million (2025-2030)
  • Figure 41. South America Human Immunoglobulin Share (%), by Country
  • Figure 42. Asia Pacific Human Immunoglobulin Share (%), by Country
  • Figure 43. Europe Human Immunoglobulin Share (%), by Country
  • Figure 44. MEA Human Immunoglobulin Share (%), by Country
  • Figure 45. North America Human Immunoglobulin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Shire (United States)
  • CSL (United States)
  • Grifols (Spain)
  • Octapharma (Switzerland)
  • Biotest (Germany)
  • China National Pharmaceutical Group Corporation (China)
  • Hualan Bio (China)
  • Shanxi Kangbao Biological Product (China)
  • Pfizer Inc. (United States)
  • Kedrion Biopharma Inc. (United States)
Additional players considered in the study are as follows:
Shuanglin Bio Pharma (China) , Sichuan Yuanda Shuyang Pharmaceutical (China)
Select User Access Type

Key Highlights of Report


Mar 2024 212 Pages 71 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Immunoglobulin research Quantitative research analysis
Global Human Immunoglobulin research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Shire (United States), CSL (United States), Grifols (Spain), Octapharma (Switzerland), Biotest (Germany), China National Pharmaceutical Group Corporation (China), Hualan Bio (China), Shanxi Kangbao Biological Product (China), Pfizer Inc. (United States) and Kedrion Biopharma Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Adoption of Subcutaneous owing to Improved Patients Advantages" is seen as one of major influencing trends for Human Immunoglobulin Market during projected period 2023-2030.
The Human Immunoglobulin market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Human Immunoglobulin research Report?

Have a Query? Click Here

Other Related Reports

Biological Indicator Incubator Comprehensive Study by Type (Steam Indicator, EO (Ethylene Oxide) Gas Indicator, Others), End Users (Laboratories, Clinical Research Organizations, Academic Research Ce...
$ 3450
Separation Systems for Commercial Biotechnology Comprehensive Study by Application (Vaccines, Hormones, Proteins, Enzymes, Others), End-User (Pharmaceutical, Food & Cosmetics, Agriculture, Life Scien...
$ 3650
Lab Dishes Comprehensive Study by Type (Reusable, Disposable), Application (University Laboratory, Research Laboratory, Other), Dish Type (Petri Dishes, Evaporating Dishes, Crystallizing Dishes, Othe...
$ 3350
Animal Vaccine Comprehensive Study by Type (Live attenuated vaccines, Inactivated vaccines, Toxoid vaccines, Recombinant vaccines, Other vaccines.), Application (Porcine, Poultry, Livestock, Companio...
$ 3350
Animal Model Comprehensive Study by Type (Rats, Mice, Rabbits, Dogs, Pigs, Cats, Others), Application (Physiology, Toxicology, Cancer Research, Neurological Research, Biomedical Research, Genetic Res...
$ 3750
Stem Cell Banking Comprehensive Study by Type (Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Others), Application (Personalized Banking Applications, Research Applications {Di...
$ 3750